PTC’s Cystic Fibrosis Drug Performs Well In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Foundation says drug is exception to rule, and fronts more funding.
You may also be interested in...
EMD Serono Buys $19M Seat At MS Society’s Research Table
Unlike some other industry/charity couplings, pharma foots the VC bill.
EMD Serono Buys $19M Seat At MS Society’s Research Table
Unlike some other industry/charity couplings, pharma foots the VC bill.
More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: